

Report to:	Board of Directors	Agenda item:	22c
Date of Meeting:	2 November 2022		

Title of Report:	Review of Audit Committee Terms of Reference
Status:	Approval
Author:	Adewale Kadiri, Head of Corporate Governance
Board Sponsor:	Antony Durbacz, Non-Executive Director
Appendices	Appendix 1: Terms of Reference

1.	Executive Summary of the Report
<p>The Audit and Risk Committee's Terms of Reference define the committee's structure and purpose, and how it carries out its functions.</p> <p>At the Committee's meeting in December 2021, it approved a range of changes to the Terms of Reference, including clarification of its role in relation to the Board Assurance Framework, as well as its responsibilities in relation to counter fraud and security management. These changes were ratified by the Board at its meeting in January 2022.</p> <p>The Committee conducted a further review of the Terms of Reference in September 2022, but in view of the comprehensiveness of the previous work, it is not proposed that any additional changes be made, with the exception that senior clinical representation be provided at each meeting of the Committee.</p>	

2.	Recommendations (Note, Approve, Discuss)
<p>The Board is asked to consider the changes and approve the updated Terms of Reference of the Audit and Risk Committee</p>	

3.	Legal / Regulatory Implications
<p>The role of the Audit and Risk Committee is key to the maintenance of effective corporate and financial management systems in the Trust. The Board relies on the Committee to gain assurance in respect of a number of key regulatory and governance requirements, including those imposed by the CQC and NHSE/I. It also ensures that the Trust's approaches in areas such as counter-fraud, the management of interests and gifts and cyber-security are in line with accepted best practice.</p>	

4.	Risk (Threats or opportunities, link to a risk on the Risk Register, Board Assurance Framework etc)
None	

5.	Resources Implications (Financial / staffing)
Not applicable	

6.	Equality and Diversity
Not applicable	

Author: Adewale Kadiri, Head of Corporate Governance Approved by: Antony Durbacz, Non-Executive Director Agenda Item: 22c	Date: 24 October 2022 Version: 1.0
Page 1 of 2	

7.	References to previous reports
This is an annual review. The previous year's review was completed in December 2021.	

8.	Freedom of Information
Public	